- Home
- ANGI vs LBPH Comparison
ANGI vs LBPH Comparison
Compare ANGI & LBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGI
- LBPH
- Stock Information
- Founded
- ANGI 2017
- LBPH 2020
- Country
- ANGI United States
- LBPH United States
- Employees
- ANGI N/A
- LBPH N/A
- Industry
- ANGI Advertising
- LBPH Biotechnology: Pharmaceutical Preparations
- Sector
- ANGI Consumer Discretionary
- LBPH Health Care
- Exchange
- ANGI Nasdaq
- LBPH Nasdaq
- Market Cap
- ANGI 1.3B
- LBPH 1.4B
- IPO Year
- ANGI 2017
- LBPH 2021
- Fundamental
- Price
- ANGI $1.72
- LBPH $59.69
- Analyst Decision
- ANGI Buy
- LBPH Buy
- Analyst Count
- ANGI 8
- LBPH 8
- Target Price
- ANGI $3.25
- LBPH $52.29
- AVG Volume (30 Days)
- ANGI 826.0K
- LBPH 1.1M
- Earning Date
- ANGI 11-11-2024
- LBPH 11-07-2024
- Dividend Yield
- ANGI N/A
- LBPH N/A
- EPS Growth
- ANGI N/A
- LBPH N/A
- EPS
- ANGI 0.06
- LBPH N/A
- Revenue
- ANGI $1,217,676,000.00
- LBPH N/A
- Revenue This Year
- ANGI N/A
- LBPH N/A
- Revenue Next Year
- ANGI $1.32
- LBPH N/A
- P/E Ratio
- ANGI $23.81
- LBPH N/A
- Revenue Growth
- ANGI N/A
- LBPH N/A
- 52 Week Low
- ANGI $1.65
- LBPH $3.60
- 52 Week High
- ANGI $3.10
- LBPH $59.95
- Technical
- Relative Strength Index (RSI)
- ANGI 25.30
- LBPH 79.25
- Support Level
- ANGI $2.50
- LBPH $59.71
- Resistance Level
- ANGI $2.65
- LBPH $59.87
- Average True Range (ATR)
- ANGI 0.15
- LBPH 0.23
- MACD
- ANGI -0.08
- LBPH -0.92
- Stochastic Oscillator
- ANGI 0.00
- LBPH 76.99
About ANGI Angi Inc.
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. The Company has three operating segments namely, Ads and Leads that generate maximum revenue, Services, and International (Europe and Canada). The company operates under multiple brands that including Angi, HomeAdvisor, and Handy. The majority of the revenue is earned from the United States.
About LBPH Longboard Pharmaceuticals Inc.
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.